Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23324564)

1.

The beginning of the end for serogroup B meningococcus?

Snape MD, Pollard AJ.

Lancet. 2013 Mar 9;381(9869):785-7. No abstract available.

PMID:
23324564
2.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators.

Lancet Infect Dis. 2012 Aug;12(8):597-607. Epub 2012 May 7.

PMID:
22569484
3.

Prevention of serogroup B meningococcal disease.

Stephens DS.

Lancet. 2012 Feb 18;379(9816):592-4. doi: 10.1016/S0140-6736(11)61934-X. Epub 2012 Jan 18. No abstract available.

PMID:
22260987
4.

Vaccines targeting serogroup B meningococci.

Taha MK, Deghmane AE.

Lancet Infect Dis. 2012 Aug;12(8):578-9. doi: 10.1016/S1473-3099(12)70093-2. Epub 2012 May 7. No abstract available.

PMID:
22569483
5.

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group.

Lancet. 2013 Mar 9;381(9869):825-35. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23324563
6.

Standardised case definitions for adverse events following immunisation.

Heininger U.

Lancet. 2013 Jun 29;381(9885):2250-1. doi: 10.1016/S0140-6736(13)61477-4. No abstract available.

PMID:
23809555
7.

Standardised case definitions for adverse events following immunisation - Authors' reply.

Vesikari T.

Lancet. 2013 Jun 29;381(9885):2251. doi: 10.1016/S0140-6736(13)61478-6. No abstract available.

PMID:
23809558
8.

New frontiers in meningococcal vaccines.

Anderson AS, Jansen KU, Eiden J.

Expert Rev Vaccines. 2011 May;10(5):617-34. doi: 10.1586/erv.11.50. Review.

PMID:
21604983
9.
10.
11.

Whole cell vaccination for meningococcus: Lessons from an idea whose time has gone.

Labrie JE 3rd, Keiser PB.

Hum Vaccin. 2010 Apr;6(4):360-5. Epub 2010 Apr 27. Review.

PMID:
20372072
12.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.

Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.

PMID:
22260988
13.

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group.

JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.

PMID:
22318278
14.

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B, Nøkleby H.

Clin Diagn Lab Immunol. 2005 May;12(5):599-605.

15.

[Group B meningococcal invasive infections: an unresolved public health problem].

Crisinel PA, Posfay-Barbe KM.

Rev Med Suisse. 2011 Feb 23;7(283):447-50. French.

PMID:
21452513
16.

Pfizer’s men B vaccine shows promise in phase 2.

[No authors listed]

Hum Vaccin Immunother. 2012 Aug;8(8):1016-7. No abstract available.

PMID:
23359878
17.

Meningococcal group B vaccines.

Findlow J.

Hum Vaccin Immunother. 2013 Jun;9(6):1387-8. doi: 10.4161/hv.24689. Epub 2013 Jun 6. Review.

18.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

19.

Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.

Toneatto D, Oster P, deBoer AC, Emerson A, Santos GF, Ypma E, DeTora L, Pizza M, Kimura A, Dull P.

Hum Vaccin. 2011 Jul;7(7):781-91. doi: 10.4161/hv.7.7.15997. Epub 2011 Jul 1.

PMID:
21734467
20.

Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines.

Marshall H, Clarke M, Sullivan T.

Vaccine. 2014 Jan 9;32(3):338-44. doi: 10.1016/j.vaccine.2013.11.042. Epub 2013 Nov 21.

PMID:
24269618
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk